Medical technology company Stryker (NYSE:SYK) will be reporting earnings tomorrow after market close. Here’s what investors should know.
Stryker beat analysts’ revenue expectations by 1.4% last quarter, reporting revenues of $6.44 billion, up 10.7% year on year. It was a strong quarter for the company, with a solid beat of analysts’ organic revenue estimates and a decent beat of analysts’ EPS estimates.
Is Stryker a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Stryker’s revenue to grow 8.4% year on year to $5.68 billion, slowing from the 9.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.73 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Stryker has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.5% on average.
Looking at Stryker’s peers in the medical devices & supplies - diversified segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 20.9%, beating analysts’ expectations by 2%, and Abbott Laboratories reported revenues up 4%, in line with consensus estimates. Boston Scientific traded up 6.5% following the results while Abbott Laboratories was also up 3.8%.
Read our full analysis of Boston Scientific’s results here and Abbott Laboratories’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the medical devices & supplies - diversified stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. Stryker’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $421.86 (compared to the current share price of $370.92).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.